Sarepta Therapeutics, Inc. (SRPT)
-NasdaqGM | Prev Close: | 36.65 |
|---|
| Open: | N/A |
|---|
| Bid: | 30.00 x 500 |
|---|
| Ask: | 37.70 x 300 |
|---|
| 1y Target Est: | 45.46 |
|---|
| Beta: | 0.94 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.30 - 45.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,982,270 |
|---|
| Market Cap: | 1.17B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -5.62 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- SAREPTA THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Playat Seeking Alpha(Wed, May 15)
- 3 Biotech Stocks With Potentialat Seeking Alpha(Tue, May 14)
- Sarepta Therapeutics to Present Company Overview at Upcoming ConferencesMarketwired(Fri, May 10)
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarinat TheStreet(Fri, May 10)
- Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Facebook’s Potential Waze Purchase, Sarepta Doesn’t Fall As Hard as Expected and 3 Other Hot Stocksat Wall St. Cheat Sheet(Thu, May 9)
- Sarepta climbs after saying documents to be submitted this monthat theflyonthewall.com(Thu, May 9)
- Sarepta's Meaningless Q1 Resultsat Motley Fool(Thu, May 9)
- Sarepta Therapeutics Earnings: Here’s Why Investors are Excited Nowat Wall St. Cheat Sheet(Thu, May 9)
- Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET todayCCBN(Thu, May 9)
- Q1 2013 Sarepta Therapeutics Inc Earnings Release - Before Market OpenCCBN(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 38.23 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -3.52 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.71 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -0.50 |
|---|
Business Summary
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases.
View More